Taking immunogenicity assessment of therapeutic proteins to the next level.

Therapeutic proteins provide innovative and effective therapies for numerous diseases. However, some of these products are associated with unwanted immunogenicity that may lead to clinical consequences such as reduced or loss of efficacy, altered pharmacokinetics (PK), general immune and hypersensitivity reactions, and neutralisation of the natural counterpart (e.g. the physiological hormone). Regulatory guidance on immunogenicity assessment needs to take into consideration a great diversity of products, indications and patient populations as well as constantly advancing manufacturing technologies. Such guidance needs to be sufficiently specific while, at the same time, allowing interactive discussion and adjusted benefit-risk weighing of each product on a case-by-case basis, e.g. for a unique treatment of a life threatening disease acceptable treatment risks may differ considerably from the ones in case of less serious disease. This theme was the focus of the international conference "Taking immunogenicity assessment of therapeutic proteins to the next level", held at the Paul-Ehrlich-Institut in Langen, Germany, on the 10-11. June 2010. The objectives of the conference were to highlight how the field could move from that of a mere description of risk factors to a system of risk assessment and mitigation, as well as an understanding of the impact of unwanted immunogenicity on the overall benefit/risk consideration for a medicinal product. More than 150 experts from industry, academia and regulatory authorities worldwide discussed the phenomenon of undesired immunogenicity from different perspectives. The conference focussed on issues relevant to three areas: (1) new European guidelines that are currently the subject of discussion; (2) testing strategies for immunogenicity assessment; and (3) scientific progress on the product-related factors that may contribute to the development of pathogenesis of immunogenicity, in particular in the field of protein aggregation and post-translational modifications. This report provides an overview of issues, insights, and conclusions that were discussed and achieved during the meeting.

[1]  Quynh-Thu Le,et al.  Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. , 2008, The New England journal of medicine.

[2]  A. Minagar,et al.  Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial. , 2008, Archives of neurology.

[3]  M. Silverberg,et al.  Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis , 2009, Gut.

[4]  M. Bala,et al.  Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  W. White,et al.  Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers. , 2009, Clinical therapeutics.

[6]  D. Miller,et al.  The incidence and significance of anti-natalizumab antibodies , 2007, Neurology.

[7]  T. Platts-Mills,et al.  Anaphylaxis syndromes related to a new mammalian cross-reactive carbohydrate determinant. , 2009, The Journal of allergy and clinical immunology.

[8]  C. Hausl,et al.  Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors , 2007, British journal of haematology.

[9]  I. Lasters,et al.  Strategies for preclinical immunogenicity assessment of protein therapeutics. , 2009, IDrugs : the investigational drugs journal.

[10]  J C Ryff,et al.  Clinical investigation of the immunogenicity of interferon-alpha 2a. , 1997, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[11]  A. Sette,et al.  Isoaspartyl Post-translational Modification Triggers Autoimmune Responses to Self-proteins* , 1999, The Journal of Biological Chemistry.

[12]  G. Raskob,et al.  Heparin-Induced Thrombocytopenia , 2013, Thrombosis and Haemostasis.

[13]  English Only,et al.  GUIDELINES ON EVALUATION OF SIMILAR BIOTHERAPEUTIC PRODUCTS (SBPs) , 2009 .

[14]  J. Berlin,et al.  High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Briggs,et al.  Glycoengineering of therapeutic glycoproteins: in vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues. , 2001, Biochemistry.

[16]  L. Kappos,et al.  Neutralizing antibodies and efficacy of interferon β-1a , 2005, Neurology.

[17]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[18]  W. Weitschies,et al.  Close Approximation of Two Platelet Factor 4 Tetramers by Charge Neutralization Forms the Antigens Recognized by HIT Antibodies , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[19]  J. Sims,et al.  On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models. , 2010, Basic & clinical pharmacology & toxicology.

[20]  P. Rutgeerts,et al.  Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. , 2009, Gastroenterology.

[21]  Ryff Jc,et al.  Clinical investigation of the immunogenicity of interferon-alpha 2a. , 1997 .

[22]  K. Bendtzen,et al.  Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's Disease , 2008, The American Journal of Gastroenterology.

[23]  R. Jefferis,et al.  Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. , 2009, Trends in pharmacological sciences.

[24]  J. Arnout,et al.  Factor VIII Inhibitors in Previously Treated Haemophilia A Patients with a Double Virus-inactivated Plasma Derived Factor VIII Concentrate , 1997, Thrombosis and Haemostasis.

[25]  Z. Shriver,et al.  Chinese hamster ovary cells can produce galactose-α-1,3-galactose antigens on proteins , 2010, Nature Biotechnology.

[26]  K. Peerlinck,et al.  Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[27]  J. Vermylen,et al.  A Higher than Expected Incidence of Factor VIII Inhibitors in Multitransfused Haemophilia A Patients Treated with an Intermediate Purity Pasteurized Factor VIII Concentrate , 1993, Thrombosis and Haemostasis.

[28]  T. Ittermann,et al.  Platelet factor 4 binds to bacteria , inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia , 2011 .

[29]  C. Schneider,et al.  Toward biosimilar monoclonal antibodies , 2008, Nature Biotechnology.

[30]  Huub Schellekens,et al.  Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. , 2006, Journal of Pharmacy and Science.

[31]  N. Casadevall,et al.  The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. , 2005, Kidney international.

[32]  Huub Schellekens,et al.  Immunological mechanism underlying the immune response to recombinant human protein therapeutics. , 2010, Trends in pharmacological sciences.

[33]  Li Yang,et al.  Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. , 2007, Analytical biochemistry.

[34]  A. Rosenberg,et al.  Effects of protein aggregates: An immunologic perspective , 2006, The AAPS Journal.

[35]  M. Allison,et al.  Enhanced immunogenicity of aldehyde‐bearing antigens: a possible link between innate and adaptive immunity , 2000, European journal of immunology.

[36]  E. Kuipers,et al.  Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease , 2008, Alimentary pharmacology & therapeutics.

[37]  Roy Jefferis,et al.  Contrasting glycosylation profiles between Fab and Fc of a human IgG protein studied by electrospray ionization mass spectrometry. , 2007, Journal of immunological methods.

[38]  Marie-Paule Lefranc,et al.  Human immunoglobulin allotypes , 2009, mAbs.

[39]  Huub Schellekens,et al.  Immunogenicity of biopharmaceuticals. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.